Nicolas Barry Delongchamps
Overview
Explore the profile of Nicolas Barry Delongchamps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manfredini G, Anract J, Barry Delongchamps N
Fr J Urol
. 2025 Feb;
35(5):102870.
PMID: 39983905
Objective: To evaluate the accuracy of bladder scanners in measuring bladder volume and to compare their precision. Method: MEDLINE and Cochrane databases were searched from January 1, 1990 to December...
2.
Klein C, Anract J, Pinar U, Lacroix X, Mansour R, Robert G, et al.
World J Urol
. 2025 Jan;
43(1):75.
PMID: 39820625
Introduction: This study aimed to evaluate the safety and efficacy of HoLEP in patients aged > 85 years with indwelling catheter (IDC). Methods: We retrospectively analyzed our bicentric HoLEP database...
3.
Barry Delongchamps N, Peltier A, Potiron E, Bladou F, Anract J, Diamand R, et al.
BJUI Compass
. 2025 Jan;
5(12):1307-1313.
PMID: 39744070
Objective: The aim of this study was to assess the precision and safety of targeted microwave ablation (TMA) using organ-based tracking (OBT) fusion, in patients with intermediate risk prostate cancer....
4.
Anract J, Klein C, Pinar U, Roupret M, Barry Delongchamps N, Robert G
Eur Urol Oncol
. 2024 Dec;
8(1):213-214.
PMID: 39709258
No abstract available.
5.
Oderda M, Diamand R, Abou Zahr R, Anract J, Assenmacher G, Barry Delongchamps N, et al.
World J Urol
. 2024 Sep;
42(1):535.
PMID: 39320521
Purpose: To evaluate biopsy-related complications and detection rates of any PCa and clinically significant PCa (csPCa, intended as grade group ≥ 2) between MRI-targeted TP fusion biopsies (TPBx) and TR...
6.
Anract J, Klein C, Pinar U, Roupret M, Barry Delongchamps N, Robert G
Eur Urol Oncol
. 2024 Sep;
8(1):145-151.
PMID: 39256094
Background And Objective: Histopathological examination of surgical specimens for benign prostatic hyperplasia (BPH) can detect incidental prostate cancer (iPCa). The aim of our study was to develop a predictive model...
7.
Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno H, Lefebvre Y, et al.
Prostate Cancer Prostatic Dis
. 2024 Jul;
28(1):173-179.
PMID: 39048664
Background: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (mpMRI), present a clinical challenge due to their equivocal nature in predicting clinically significant...
8.
Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno H, Lefebvre Y, et al.
World J Urol
. 2024 Jun;
42(1):372.
PMID: 38866949
Purpose: Magnetic resonance imaging (MRI) is a promising tool for risk assessment, potentially reducing the burden of unnecessary prostate biopsies. Risk prediction models that incorporate MRI data have gained attention,...
9.
Baudewyns A, Guenzel K, Halinski A, Dariane C, Delavar G, Anract J, et al.
World J Urol
. 2024 May;
42(1):322.
PMID: 38747982
Purpose: Utility of prostate-specific antigen density (PSAd) for risk-stratification to avoid unnecessary biopsy remains unclear due to the lack of standardization of prostate volume estimation. We evaluated the impact of...
10.
Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, et al.
Eur Urol Focus
. 2024 Mar;
10(5):805-811.
PMID: 38508895
Background And Objective: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the...